Abstract
Human Gene TherapyVol. 34, No. 11-12 Gene Therapy BriefsFood and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene TherapyAlex PhilippidisAlex Philippidis*Correspondence: E-mail Address: aphilippidis@liebertpub.comMary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.Search for more papers by this authorPublished Online:16 Jun 2023https://doi.org/10.1089/hum.2023.29243.bfsAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 34Issue 11-12Jun 2023 InformationCopyright 2023, by Mary Ann Liebert, Inc., publishersTo cite this article:Alex Philippidis.Food and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene Therapy.Human Gene Therapy.Jun 2023.477-480.http://doi.org/10.1089/hum.2023.29243.bfsPublished in Volume: 34 Issue 11-12: June 16, 2023PDF download
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
